Name: 글로벌 시장 동향
SKU: PH135
Availability: InStock

보고서 요약(국문)

개요
전 세계 황반부종 시장은 2023년 YY백만 달러에 도달했으며, 2024년부터 2031년까지 연평균 성장률(CAGR) YY%로 성장하여 2031년에는 YY백만 달러에 이를 것으로 예상됩니다.
황반부종은 망막(눈 뒤쪽에 있는 빛에 민감한 조직층)의 일부가 붓는 질환입니다. 황반부종이 있는 사람은 시야가 흐릿해질 수 있지만, 치료를 통해 부기를 줄이고 시력 손실을 예방할 수 있습니다.
황반부종은 혈관에서 혈액이 망막의 황반으로 새어 들어가면서 발생합니다. 이로 인해 황반이 부어오르고 시야가 흐릿해집니다. 황반부종의 원인은 다양하며, 가장 흔한 원인은 당뇨병성 망막병증입니다. 당뇨병성 망막병증은 당뇨병 환자에게 시력 손실을 유발하는 안과 질환입니다. 당뇨병성 망막병증으로 인해 황반부종이 발생하면 이를 당뇨병성 황반부종(DME)이라고 합니다.
시야 흐림과 시간이 지남에 따라 악화되는 시력은 황반부종의 주요 증상입니다. 일반적으로 황반부종 진단에는 형광안저조영술, 광간섭단층촬영(OCT), 암슬러 격자법 등이 사용됩니다.
시장 동향: 성장 동인
다양한 연령대에서 증가하는 당뇨병 유병률
전 세계 황반부종 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 당뇨병 유병률의 증가는 시장 성장을 촉진하는 주요 요인입니다. 현재 당뇨병 환자가 급증하고 있으며, 이는 황반부종 발생률 증가의 주요 원인 중 하나입니다.
당뇨병성 황반부종은 전체 황반부종 사례 중 가장 흔하게 발생하는 질환 중 하나입니다. NCBI에 따르면 미국에서는 40세 이상 당뇨병 환자의 3.8%가 당뇨병성 황반부종을 앓고 있습니다. 전 세계 당뇨병 환자 중 약 4~7%가 당뇨병성 황반부종의 영향을 받고 있습니다.
성장 저해 요인
전 세계 황반부종 시장은 또한 여러 가지 어려움과 제약에 직면해 있습니다. 주요 제약 요인 중 하나는 황반부종 치료 및 요법의 높은 비용으로, 특히 저소득층 및 의료 서비스 소외 지역 사회의 환자들이 치료를 받는 데 어려움을 겪게 합니다. 또한, 규제 장벽과 보험금 지급 정책은 새로운 당뇨병성 황반부종 치료법의 도입을 저해하여, 필요한 환자들이 혁신적인 치료법을 이용하지 못하게 할 수 있습니다. 더욱이, 당뇨병성 황반부종의 복잡한 특성과 다인성 병인은 표적화되고 효과적인 치료 전략 개발에 어려움을 야기합니다.
세분화 분석
전 세계 황반부종 시장은 질병 유형, 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
레이저 치료 부문은 전 세계 황반부종 시장 점유율의 약 56.4%를 차지했습니다.
안과 레이저 수술은 황반부종 치료에 가장 많이 사용되는 치료 기술 중 하나입니다. 이는 황반부종 치료에 사용할 수 있는 가장 안전한 기술 중 하나이므로, 이 관점은 매우 중요합니다. 기존 치료법 및/또는 레이저 치료는 황반부종의 진행을 늦추거나 감소시키는 효과가 있습니다. 독립적인 치료법으로는 국소/격자 광응고술 또는 광역학 치료(PDT)가 있으며, 이는 두 가지 목적을 위해 개발되었습니다. 첫 번째 목적은 시력에 중요한 역할을 하는 망막 황반 부위에 발생하는 부기(수분)를 줄이는 것입니다.
레이저 치료는 황반부종을 감소시키고 망막 건강에 상당한 이점을 제공함으로써 시력 저하를 막는 데 도움이 됩니다. 이는 당뇨병성 황반부종(DME)과 같이 치료하지 않고 방치할 경우 시력이 점진적으로 저하되는 질환에서 특히 중요합니다. 미국 국립안연구소(NIA)에 따르면, 치료를 통해 황반부종 환자의 50~60%를 부작용 없이 완치할 수 있습니다.
지역 분석
북미 지역은 전 세계 황반부종 시장 점유율의 약 43.2%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역에서 황반부종 발병률이 증가하고 사람들의 인식이 높아짐에 따라 시장 성장이 촉진되고 있습니다.
당뇨병성 황반부종(DME)은 당뇨병 유병률이 높은 북미 지역에서 황반부종 사례의 주요 원인입니다. 미국에서는 약 770만 명이 당뇨병성 망막병증을 앓고 있는 것으로 추정되며, 이는 DME를 유발할 수 있는 질환입니다. 황반부종은 망막 정맥 폐쇄 및 염증성 질환을 포함한 다양한 원인으로 발생할 수 있지만, 이 지역에서는 당뇨병성 망막병증이 주요 원인으로 남아 있습니다.
선진 의료 시설을 갖춘 도시에서는 전문의와 의료 자원에 대한 접근성이 더 좋기 때문에 항 VEGF 주사와 같은 새로운 치료법의 도입이 더 활발할 수 있습니다. 북미(특히 미국과 캐나다)의 규제 환경은 견고하여 새로운 치료법이 승인 전에 엄격한 평가를 거치도록 보장합니다. 이러한 과정을 통해 황반부종 치료의 안전성과 효능에 대한 높은 기준을 유지할 수 있습니다.

시장 세분화
질병 유형별
• 당뇨병성 황반부종
• 낭포성 황반부종
치료 유형별
• 주사
• 안약
• 레이저 치료
• 안과 수술
최종 사용자별
• 병원 및 클리닉
• 안과 센터
• 연구 기관 및 실험실
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
황반부종 시장의 주요 글로벌 업체로는 Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Allergan (AbbVie), Bayer, Alimera Sciences, Bausch 등이 있습니다. 롬브, 제넨텍, 산텐 파마슈티카, 오프토텍 코퍼레이션.
주요 개발 사항
 2023년 9월, 제넨텍은 라니비주맙(루센티스)의 맞춤형 제형을 장기간에 걸쳐 안구에 직접 지속적으로 전달하는 포트 전달 시스템(PDS)을 개발했습니다. 이 시스템은 약물의 지속적인 전달을 통해 잦은 주사 필요성을 최소화함으로써 신생혈관성 황반변성(nAMD) 및 황반부종을 포함한 기타 망막 질환 환자의 치료 부담을 줄이는 것을 목표로 합니다.

 2023년 3월, 산텐 파마슈티카는 DE-128(시롤리무스)의 3상 임상시험에서 긍정적인 결과를 발표했습니다. 산텐은 비감염성 포도막염 치료를 위한 DE-128(시롤리무스) 안구내 주사의 효과를 평가하는 3상 DERBY 연구에서 긍정적인 주요 결과를 보고했습니다. 시롤리무스는 눈의 염증과 신생혈관 생성을 억제하는 mTOR 억제제입니다. 본 연구는 위약 주사 대비 시력 개선 및 중심부 망막하층 두께 감소에 유의미한 효과를 보여, 포도막염 관련 황반부종 치료에 잠재적인 이점이 있음을 입증했습니다.
보고서 구매 이유:

• 질병 유형, 치료 유형, 최종 사용자 및 지역별 글로벌 황반부종 시장 세분화를 시각화하고 주요 상업 자산 및 업체들을 파악할 수 있습니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 글로벌 황반부종 시장 수준의 다양한 데이터가 담긴 엑셀 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑을 제공합니다.

글로벌 황반부종 치료 시장 보고서는 약 62개의 표, 52개의 그림, 그리고 181페이지 분량으로 구성됩니다.

2024년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The Global Macular Edema Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Macular edema is swelling in part of the retina (the light-sensitive layer of tissue at the back of your eye). People with macular edema may have blurry vision, but treatment can help reduce the swelling and prevent vision loss.
Macular edema happens when blood vessels leak into a part of the retina called the macula. This makes the macula swell, causing blurry vision. Many different conditions can cause macular edema. The most common one is diabetic retinopathy — an eye condition that causes vision loss in people with diabetes. When diabetic retinopathy causes macular edema, it is called diabetic macular edema (DME).
Blurry vision and vision that gets worse over time are the main symptoms of macular edema. Generally, detection of macular edema is done by fluorescein angiogram, optical coherence tomography (OCT), amsler grid methods.
Market Dynamics: Drivers
Rising prevalence of diabetes in various age groups
The demand for the global macular edema market is driven by multiple factors. The rising prevalence of diabetes propels the market growth. Nowadays people affected by diabetes are increasing a lot which is a major cause for the rise of macular edema in people.
Diabetic macular edema is one of the most frequently recorded cases in the overall macular edema cases. According to NCBI, in the US, 3.8% of people who are above the age of 40 years and suffer from diabetes, suffer from diabetic macular edema. In the entire global population who suffer from diabetes, around 4 – 7% of people are being affected by diabetic macular edema.
Restraints
The global macular edema market also faces several challenges and restraints. One key restraint is the high cost of macular edema treatments and therapies, which can limit access to care for patients, particularly in low-income and underserved communities. Additionally, regulatory hurdles and reimbursement policies may create barriers to the adoption of new diabetic macular edema treatments, delaying access to innovative therapies for patients in need. Furthermore, the complex nature of DME and its multifactorial pathogenesis present challenges for developing targeted and effective treatment strategies.
Segment Analysis
The global macular edema market is segmented based on disease type, treatment type, end-users, and region.
The segment laser treatment accounted for approximately 56.4% of the global macular edema market share
Laser surgery of the eye is among the most frequently used therapy techniques that are applied to treat macular edema. This is among the safest techniques that can be used to address macular edema, thus the significance of this viewpoint. The Conventional and/or Laser treatment has the following benefits, it slows down the development or reduces macular edema. Free-standing treatments include focal/grid photocoagulation or photodynamic therapy (PDT) which formed strategies for two purposes. The first one was attempted to reduce the swelling (edema) that develops in the macula area of the retina, which is responsible for sharpness.
Laser treatment helps to stop vision from getting any worse because the procedure helps reduce macular edema while having a considerably beneficial impact on the health of the retina. This about is important in conditions such as DME where if the condition is left untreated, the individual will progressively lose their vision. According to National Eye Institute, by treatment 50 to 60% of the macular edema cases can be completely cured without any side effects.
Geographical Analysis
North America accounted for approximately 43.2% of the global macular edema market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of macular edema, and growing awareness among people, in this region, help to propel the market.
Diabetic Macular Edema (DME) is a significant contributor to macular edema cases in North America due to the high prevalence of diabetes. Approximately 7.7 million people in the United States are estimated to have diabetic retinopathy, a condition that can lead to DME. Overall, macular edema can occur due to various causes including retinal vein occlusion and inflammatory conditions, but diabetic retinopathy remains a primary driver in this region.
In urban centers with advanced healthcare facilities, the adoption of newer treatments like anti-VEGF injections may be more prevalent due to better access to specialists and resources. The regulatory landscape in North America (specifically in the United States and Canada) is robust, ensuring that new therapies undergo rigorous evaluation before approval. This process helps maintain high standards of safety and efficacy in treatments for macular edema.
Market Segmentation
By Disease Type
• Diabetic macular edema
• Cystoid macular edema
By Treatment Type
• Injections
• Eye Drops
• Laser Treatment
• Eye surgery
By End Users
• Hospitals and clinics
• Opthamology centers
• Research institutes and Laboratories
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the globular macular edema market include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Allergan (AbbVie), Bayer, Alimera Sciences, Bausch Lomb, Genentech, Santen Pharmaceutica, Ophthotech Corporation.
Key Developments
 In September 2023, Genentech has been developing a Port Delivery System (PDS) that continuously delivers a customized formulation of ranibizumab (Lucentis) directly into the eye over extended periods. This approach aims to reduce the treatment burden for patients with nAMD and potentially other retinal diseases, including macular edema, by providing sustained delivery of the drug and minimizing the need for frequent injections.
 In March 2023, Santen Pharmaceuticals announced Positive Phase 3 Results for DE-128 (Sirolimus). Santen reported positive topline results from the Phase 3 DERBY study evaluating DE-128 (sirolimus) intravitreal injection for the treatment of non-infectious uveitis. Sirolimus is an mTOR inhibitor that suppresses inflammation and neovascularization in the eye. The study showed significant improvements in visual acuity and reduction in central subfield thickness compared to sham injections, demonstrating potential benefits in treating macular edema associated with uveitis.
Why Purchase the Report?
• To visualize the global macular edema market segmentation based on disease type, treatment type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global macular edema market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global macular edema treatment market report would provide approximately 62 tables, 52 figures, and 181 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of diabetes in all age groups
4.1.1.2. Increase in aging of the overall global population
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.2.2. The treatment procedures are complicated
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Disease Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Diabetic macular edema
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Cystoid macular edema
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment
7.2. Injections
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Eye drops
7.4. Laser treatment
7.5. Eye surgery
8. By End-Users
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
8.1.2. Market Attractiveness Index, By End-Users
8.2. Opthamology centers
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Research institutes and laboratories
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Novartis pharmaceuticals *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Regeneron pharmaceuticals
11.3. Roche
11.4. Allergan (ABBVie)
11.5. Bayer
11.6. Alimera sciences
11.7. Bausch Lomb
11.8. Genentech
11.9. Santen Pharmaceuticals
11.10. Opthotech Corporation
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Novartis pharmaceuticals, 4.	Key Developments, Regeneron pharmaceuticals, Roche, Allergan (ABBVie), Bayer, Alimera sciences, Bausch Lomb, Genentech, Santen Pharmaceuticals, Opthotech Corporation

표 목록 (Tables)

List of Tables

Table 1 Global Macular Edema Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Macular Edema Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Macular Edema Market Value, By End-Users, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Macular Edema Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Macular Edema Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Macular Edema Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 7 Global Macular Edema Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Macular Edema Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 9 Global Macular Edema Market Value, By End-Users, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Macular Edema Market Value, By End-Users, 2022-2031 (US$ Million)

Table 11 Global Macular Edema Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Macular Edema Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Macular Edema Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 14 North America Macular Edema Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 15 North America Macular Edema Market Value, By End-Users, 2022-2031 (US$ Million)

Table 16 North America Macular Edema Market Value, By Country, 2022-2031 (US$ Million)

Table 17 Asia-Pacific Macular Edema Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 18 Asia-Pacific Macular Edema Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Macular Edema Market Value, By End-Users, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Macular Edema Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Macular Edema Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 Europe Macular Edema Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 23 Europe Macular Edema Market Value, By End-Users, 2022-2031 (US$ Million)

Table 24 Europe Macular Edema Market Value, By Country, 2022-2031 (US$ Million)

Table 25 South America Macular Edema Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 26 South America Macular Edema Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 27 South America Macular Edema Market Value, By End-Users, 2022-2031 (US$ Million)

Table 28 South America Macular Edema Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Macular Edema Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Macular Edema Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Macular Edema Market Value, By End-Users, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Macular Edema Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Novartis Pharmaceuticals: Overview

Table 34 Novartis Pharmaceuticals: Product Portfolio

Table 35 Novartis Pharmaceuticals: Key Developments

Table 36 Regeneron Pharmaceuticals: Overview

Table 37 Regeneron Pharmaceuticals: Product Portfolio

Table 38 Regeneron Pharmaceuticals: Key Developments

Table 39 Roche: Overview

Table 40 Roche: Product Portfolio

Table 41 Roche: Key Developments

Table 42 Allergan (AbbVie): Overview

Table 43 Allergan (AbbVie): Product Portfolio

Table 44 Allergan (AbbVie): Key Developments

Table 45 Bayer: Overview

Table 46 Bayer: Product Portfolio

Table 47 Bayer: Key Developments

Table 48 Alimera Sciences: Overview

Table 49 Alimera Sciences: Product Portfolio

Table 50 Alimera Sciences: Key Developments

Table 51 Bausch Lomb: Overview

Table 52 Bausch Lomb: Product Portfolio

Table 53 Bausch Lomb: Key Developments

Table 54 Genentech: Overview

Table 55 Genentech: Product Portfolio

Table 56 Genentech: Key Developments

Table 57 Santen Pharmaceuticals: Overview

Table 58 Santen Pharmaceuticals: Product Portfolio

Table 59 Santen Pharmaceuticals: Key Developments

Table 60 Opthotech Corporation: Overview

Table 61 Opthotech Corporation: Product Portfolio

Table 62 Opthotech Corporation: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 2 Global Macular Edema Market Share, By Disease Type, 2023 & 2031 (%)

Figure 3 Global Macular Edema Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 4 Global Macular Edema Market Share, By End-Users, 2023 & 2031 (%)

Figure 5 Global Macular Edema Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Macular Edema Market Y-o-Y Growth, By Disease Type, 2023-2031 (%)

Figure 7 Diabetic Macular Edema Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 8 Cystoid Macular Edema Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 9 Global Macular Edema Market Y-o-Y Growth, By Treatment Type, 2023-2031 (%)

Figure 10 Injections Treatment Type in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 11 Eye Drops Treatment Type in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 12 Laser Treatment Treatment Type in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 13 Eye Surgery Treatment Type in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 14 Global Macular Edema Market Y-o-Y Growth, By End-Users, 2023-2031 (%)

Figure 15 Hospitals and Clinics End-Users in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 16 Opthamology Centers End-Users in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 17 Research centers and Laboratories End-Users in Global Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 18 Global Macular Edema Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 19 North America Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 20 North America Macular Edema Market Share, By Disease Type, 2023 & 2031 (%)

Figure 21 North America Macular Edema Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 22 North America Macular Edema Market Share, By End-Users, 2023 & 2031 (%)

Figure 23 North America Macular Edema Market Share, By Country, 2023 & 2031 (%)

Figure 24 Asia-Pacific Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 25 Asia-Pacific Macular Edema Market Share, By Disease Type, 2023 & 2031 (%)

Figure 26 Asia-Pacific Macular Edema Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 27 Asia-Pacific Macular Edema Market Share, By End-Users, 2023 & 2031 (%)

Figure 28 Asia-Pacific Macular Edema Market Share, By Country, 2023 & 2031 (%)

Figure 29 Europe Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 30 Europe Macular Edema Market Share, By Disease Type, 2023 & 2031 (%)

Figure 31 Europe Macular Edema Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 32 Europe Macular Edema Market Share, By End-Users, 2023 & 2031 (%)

Figure 33 Europe Macular Edema Market Share, By Country, 2023 & 2031 (%)

Figure 34 South America Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 35 South America Macular Edema Market Share, By Disease Type, 2023 & 2031 (%)

Figure 36 South America Macular Edema Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 37 South America Macular Edema Market Share, By End-Users, 2023 & 2031 (%)

Figure 38 South America Macular Edema Market Share, By Country, 2023 & 2031 (%)

Figure 39 Middle East and Africa Macular Edema Market Value, 2022-2031 (US$ Million)

Figure 40 Middle East and Africa Macular Edema Market Share, By Disease Type, 2023 & 2031 (%)

Figure 41 Middle East and Africa Macular Edema Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 42 Middle East and Africa Macular Edema Market Share, By End-Users, 2023 & 2031 (%)

Figure 43 Novartis Pharmaceuticals: Financials

Figure 44 Regeneron Pharmaceuticals: Financials

Figure 45 Roche: Financials

Figure 46 Allergan (AbbVie): Financials

Figure 47 Bayer: Financials

Figure 48 Alimera Sciences: Financials

Figure 49 Bausch Lomb: Financials

Figure 50 Genentech: Financials

Figure 51 Santen Pharmaceuticals: Financials

Figure 52 Opthotech Corporation: Financials

세계 황반부종 시장 – 2024-2031년

Global Macular Edema Market - 2024-2031